^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAVO412

    i
    Other names: TAVO412, Tavo-412
    Associations

    News

    Trials
    Company:
    Tavotek
    Drug class:
    EGFR inhibitor, c-MET inhibitor, VEGF inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Recruiting, Tavotek Biotherapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412
    1year
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Tavotek Biotherapeutics | Initiation date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial initiation date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412
    over1year
    A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Tavotek Biotherapeutics
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    TAVO412